ARWR vs FOXA · rev $829.4M vs P/E 14, rev $17.13B
Arrowhead Pharmaceuticals Inc (ARWR) versus Fox Corp Class A (FOXA) — a side-by-side from cached financials, not a winner call.
Arrowhead Pharmaceuticals Inc (ARWR) is a biotechnology company listed on US.
Fox Corp Class A (FOXA) is a entertainment company listed on US.
Latest reported ARWR revenue for 2025-09-30 was $829.4M. Net income was $30.1M. Revenue was up 23258.2% from 2024-09-30 to 2025-09-30. ARWR currently screens at market cap $10.59B.
Latest reported FOXA revenue for 2026-06-30 was $17.13B. Net income was $1.73B. Revenue was up 5.1% from 2025-06-30 to 2026-06-30. FOXA currently screens at market cap $24.50B and trailing P/E 14.1.
ARWR currently screens at market cap $10.59B. FOXA currently screens at market cap $24.50B and trailing P/E 14.1.
Not investment advice. Open the ARWR and FOXA stock pages for the full models.
Not investment advice.